🟢 Humacyte is trading 10.89% up in after-hours trading despite no new company-specific catalyst

Humacyte is trading at $0.61, up 10.89% in after-hours trading, with no new company-specific catalyst identified in available coverage.

• Shares declined 17.29% in the regular session on August 13, 2026.
• Latest earnings showed $0.4 million in Symvess sales, a $0.16 quarterly loss per share, and $410,000 in revenue versus an estimated $1.11 million.
• Broader markets were positive, but that backdrop alone does not clearly explain the after-hours rebound.